Table 1. Characteristics of the included studies.
| Study | Pt or lesions | MedianAge (year) | Dose | Median PTV (cc) | Median follow-up (months) | RP ≥grade 2 (no.) |
Dose-volume factors for RP after SBRT |
|---|---|---|---|---|---|---|---|
| Yamashita 2007[13] | 25 | 77 | 48Gy/4-6Fr | 43.9 | 17 | 7 | CI |
| Ricardi 2009[12] | 63 | 71.7 | 45Gy/3Fr or 26Gy/1Fr | NA | 30.9 | 9 | Ipsilateral MLD |
| Guckenberger 2010[8] | 59 | 67 | 37.5Gy/3Fr or 26Gy/1Fr | 33 | 13 | 11 | Total MLD, Ipsilateral MLD, V2.5–50 |
| Barriger 2012[6] | 143 | 74 | 24-66Gy/3-5Fr | 48.3 | 17 | 15 | Total MLD, V20 |
| Matsuo 2012[9] | 74 | 77 | 48Gy/4Fr | 32.5 | 31.4 | 15 | PTV, V20,V25 |
| Aibe 2013[5] | 30 | 80 | 50Gy/3-5Fr | 27.5 | 36.5 | 3 | GTV |
| Bongers 2013[7] | 79 | 75.5 | 54-60Gy/3-12Fr | 149.4 | 13 | 8 | Contralateral MLD, ITV |
| Moré 2014[10] | 20 | 68 | 34-60Gy/1-5Fr | 55.36 | 6 | 5 | NA |
| Nakamura 2016[11] | 56 | 78 | 48-56Gy/4Fr | 23.8 | 12.5 | 6 | PTV, GTV, Total MLD, V5-V50 |
MLD: mean lung dose; NA: not available; Pt: patients